Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775761 | 0.84 | NPY5R (0.50) | NPY5RHTTSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL19401299 | 0.77 | XDH (0.34) | LMNAMAPT | |
| SCHEMBL17139796 | 0.73 | KDM4E (0.36) | NPY5RKDM4EMEN1KMT2A | |
| SCHEMBL17329035 | 0.72 | DYRK1A (0.46) | NPY5RTDP1ALDH1A1KDM4ELMNA | |
| SCHEMBL21539478 | 0.72 | ESR1 (0.34) | KDM4EMAPT | |
| SCHEMBL15819689 | 0.71 | NPY5R (0.43) | NPY5RALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL30959326 | 0.71 | LMNA (0.32) | LMNA | |
| SCHEMBL28654884 | 0.71 | DAO (0.42) | SMN1; SMN2ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL31452701 | 0.70 | CHUK (0.37) | HTTSMN1; SMN2TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL5776765 | 0.69 | NPY5R (0.51) | NPY5RSMN1; SMN2L3MBTL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024233605-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-11-07 | — | — | US | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240182481-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | TANGO THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-21 | — | — | US | disclosed |
| EP-4291559-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Tango Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022174184-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | TANGO THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-4003980-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Ribon Therapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021021986-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | RIBON THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-04 | — | — | US | disclosed |
| WO-2020186220-A1 | COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2020-09-17 | — | — | WO | disclosed |
| US-10654856-B2 | Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190040072-A1 | METHOD FOR PREPARING PYRROLO[3,2-D]PYRIMIDINE COMPOUND, AND INTERMEDIATES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040072-A1 | METHOD FOR PREPARING PYRROLO[3,2-D]PYRIMIDINE COMPOUND, AND INTERMEDIATES THEREOF | DPYD, TYMS, TYMP | NPY5R 1161/4885GAA 3382/4885HTT 2781/4885 |
| US-20240368167-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | NPY5R 4220/4885GAA 683/4885HTT 3637/4885 |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | NPY5R 4220/4885GAA 683/4885HTT 3637/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | NPY5R 4220/4885GAA 683/4885HTT 3637/4885 |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | NPY5R 4220/4885GAA 683/4885HTT 3637/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | NPY5R 1144/4885GAA 3672/4885HTT 4174/4885 |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | NPY5R 4220/4885GAA 683/4885HTT 3637/4885 |
| US-20240182481-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | DPYD, TYMS, TYMP | NPY5R 351/4885GAA 2914/4885HTT 3046/4885 |
| US-10654856-B2 | Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof | DPYD, TYMS, TYMP | NPY5R 1161/4885GAA 3382/4885HTT 2781/4885 |
| US-11987584-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | NPY5R 4220/4885GAA 683/4885HTT 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.